"Beximco Pharma has had an extremely good year in 2005 and the successful floatation on Alternative Investment Market (AIM) of London Stock Exchange has enabled us to progress our strategic plans. We have continued our growth into 2006, and have already successfully launched a number of new products; most significant is the introduction of our generic bird-flu drug, Oseflu^® in the Bangladesh and other South East Asain markets. We believe, Beximco Pharma has a strong platform to continue to grow profitably both in domestic and international markets in the years to come.”

Beximco Pharma: 25 years in Healthcare business: A journey of excellence
“Beximco Pharma has long enjoyed the reputation of being a leader in setting the trends in Bangladesh Pharmaceutical Industry. 25 years have passed since we started our own operation. In the last 25 years we have led the domestic Pharmaceutical market in several dimensions. Now we have undertaken further strategic expansions to position Beximco Pharma among the top players in the global generic pharmaceutical industry.”

Distinguished operational capability
In 1980 we were small in operation but big in dreams and passionate with our vision - building a healthier tomorrow where our fellow citizens will live longer, healthier and happier. Our activities have always been centered around developing core competencies to deliver the best in the industry ensuring superior value and return to our customers.

R&D capability in both formulation and API (Active Pharmaceutical Ingredients)
R&D is another area where we have already shown our capability and led the Bangladesh Pharmaceutical Market in both formulation R&D and API R&D. Our formulation R&D capability is proven not only by the consistent quality of our products but also by our ability to introduce hi-tech, specialized products and dosage forms. The reverse engineering capability of the R&D team has enabled us to introduce innovative new products to serve the ailing people at home and abroad

 We believe, the investment in R&D unit to enhance our capability to reverse engineer and manufacture APIs will ensure one of our major competitive edges in the coming years. We have also signed agreements for collaborative research with leading international API manufacturers to strengthen our API pipeline in order to fully capitalize the WTO patent opportunity.

Sales & Marketing capability focused on brand building
Our major strength is our sales and marketing team. Our marketing team is composed of innovative people from diverse discipline. Because of the innovative & creative approach adopted by our marketing team, we have been able to create many vibrant brands like Napa, Neoceptin-R, Amdocal, Neofloxin, Tycil, Omastin, Azmasol, Bexitrol-F, Atova, Bextram Gold etc. Infact, the ability of our sales & marketing team to differentiate our brands even in a crowded generic market is our major competitive advantage.

Experience in foreign markets
Beximco Pharma always took the leading, proactive and pioneering role in exporting pharmaceuticals from Bangladesh. We are pioneer in exporting APIs, IV Fluids and hi-tech specialized products. We are the first pharmaceutical company in Bangladesh to enter CIS countries. We are also pioneer to enter African markets. Beximco Pharma is the only pharmaceutical company in Bangladesh having its operation in Singapore - one of the most stringently regulated market in Asia. We are the only company in Bangladesh to supply medicines to Raffles Hospital and KK Women & Children Hospital of Singapore. Beximco Pharma is the only company in Bangladesh to receive highest national accolade -National Export Trophy (Gold) for record three times for its outstanding contribution to pharmaceutical export.

 With our exposure, expertise and skills in overseas markets, we aim to further facilitate our market expansion strategies in coming years.

Well established partnership with world’s leading pharmaceutical companies
Beximco Pharma has well established partnerships with some of world's leading pharmaceutical companies. We started our journey partnering with Bayer AG of Germany and Upjohn Inc. of USA. We have also partnered with Roche of Switzerland and Pharma Italia Carlo Erba of Italy. Today, we contract manufacture world’s number one inhaler brand Ventolin for GlaxoSmithKline, and will soon commence to contract manufacture liquid, cream, ointment and suppository products for Novartis. On the other hand, we have outsourced two of our injectable products from Sanofi Aventis. These partnerships with world’s leading pharmaceutical companies have enabled us to acquire expertise and skills of global standard.

Future growth potential
Domestic and existing export markets
Our past and present performances clearly suggest that we have ample scope to grow even in the domestic as well as in our existing export markets. We have successfully continued our effort in registering products in the overseas markets despite the fact that we do not have the capacity at present. We would also like to explore all segments of the domestic market where our major competitors are presently enjoying free-hold due to our absence in those areas. Moreover, we have already identified some attractive niche markets where the investment is negligible as compared to its expected returns in terms of profitability. Once the new OSD (Oral Solide Dosage) plant is operational and we have the capacity, we are confident, we will be able to capitalize on these opportunities and increase our market share in the domestic market as well as in other existing export markets.

New export markets
Each year patents on pharmaceutical products expire with annual sales worth billions of dollars. Datamonitor estimates that there are blockbuster drugs coming off-patent by 2007 which have sales in excess of US $82 billion. This will be one of the key factors which will help drive generic pharmaceutical growth over the next decade. We seek to position Beximco Pharma to take advantage of this growing generic market by regularly introducing new products in our existing and new markets. We believe our low manufacturing cost will provide a competitive edge over our global competitors in any international generic pharmaceutical market. Infact, export of off-patented products in the developed and developing countries will probably remain as our single largest opportunity to grow exponentially.

As per TRIPS guidelines, Bangladesh as an LDC is now legally allowed to reverse engineer, manufacture and sell generic versions of on-patent pharmaceutical products for domestic consumption as well as for export to other LDCs. The 50 LDC countries represent a large market for pharmaceutical products with a total population of over 700 million and with an increasing demand for quality healthcare.

Contract Manufacturing
Cost of medication is becoming a major concern even in the developed countries. This particular issue coupled with severe price competition from the generic manufacturers has prompted a number of giant multinational companies to shift or outsource their production from developed to developing and less developed countries, because of huge cost advantage. It is believed that the world pharmaceutical market will continue to see more consolidation than ever across the entire value chain of the pharmaceutical business. Big companies will continue to look for suitable partners in their supply chain management in order to reduce their cost of production.

Beximco Pharma has always operated like a ‘multinational’ in terms of professionalism and infrastructure so as to build the platform to become a global player. Management has adhered to international regulatory standards which is more preferable to our international partners.

Today, we have already established ourselves as a reliable partner for a number of world’s leading pharmaceutical companies. These partnerships have given us expertise and know-how to contract manufacture products for reputed MNCs for the developed markets like UK, USA and Europe as soon as our new OSD plant gets certified by their respective agencies.